AtaiBeckley (ATAI) EBIT (2020 - 2026)
AtaiBeckley (ATAI) recorded quarterly EBIT of -$30.9 million in Q1 2026, down 51.7% quarter-over-quarter from -$20.4 million in Q1 2025, and down 51.7% on a YoY basis from -$64.0 million in Q1 2025.
AtaiBeckley (ATAI) EBIT (2020 - 2026) Analysis & Trends
AtaiBeckley has disclosed EBIT across 6 years of filings, most recently posting -$28.4 million for Q3 2025.
- EBIT for Q3 2025 came in at -$28.4 million, down 25.81% year-over-year; the trailing twelve-month figure through Sep 2025 was -$104.3 million (up 1.54% YoY), and the FY2024 annual result was -$102.7 million, up 18.16% from the prior year.
- EBIT was -$30.9 million for Q1 2026 at AtaiBeckley, down from -$20.4 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$20.4 million in Q1 2025 to a low of -$30.9 million in Q1 2026.
- The 5-year median for EBIT is -$31.9 million (2023), against an average of -$30.7 million.
- Peak annual rise in EBIT reached 48.22% in 2021, while the deepest fall reached 952.69% in 2021.
- AtaiBeckley's EBIT stood at -$45.2 million in 2021, then grew by 16.85% to -$37.6 million in 2022, then increased by 10.66% to -$33.6 million in 2023, then grew by 9.82% to -$30.3 million in 2024, then climbed by 6.04% to -$28.4 million in 2025.
- The last three EBIT figures came in at -$28.4 million (Q3 2025), -$25.3 million (Q2 2025), and -$20.4 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | -30.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.90 Mn |
| Sep 30, 2025 | -28.44 Mn |
| Jun 30, 2025 | -25.27 Mn |
| Mar 31, 2025 | -20.37 Mn |
| Mar 31, 2025 | -20.37 Mn |
| Dec 31, 2024 | -30.27 Mn |
| Sep 30, 2024 | -22.60 Mn |
| Jun 30, 2024 | -25.73 Mn |
| Mar 31, 2024 | -24.09 Mn |
| Dec 31, 2023 | -33.56 Mn |
| Sep 30, 2023 | -26.83 Mn |
| Jun 30, 2023 | -31.86 Mn |
| Mar 31, 2023 | -33.21 Mn |
| Dec 31, 2022 | -37.57 Mn |
| Sep 30, 2022 | -38.42 Mn |
| Jun 30, 2022 | -35.36 Mn |
| Mar 31, 2022 | -33.44 Mn |
| Dec 31, 2021 | -45.18 Mn |
| Sep 30, 2021 | -33.36 Mn |
| Jun 30, 2021 | -61.32 Mn |